- Home
- ANTX vs NTIP Comparison
ANTX vs NTIP Comparison
Compare ANTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- NTIP
- Stock Information
- Founded
- ANTX 2017
- NTIP 1990
- Country
- ANTX United States
- NTIP United States
- Employees
- ANTX N/A
- NTIP N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- ANTX Health Care
- NTIP Miscellaneous
- Exchange
- ANTX Nasdaq
- NTIP Nasdaq
- Market Cap
- ANTX 33.2M
- NTIP 28.6M
- IPO Year
- ANTX 2022
- NTIP 1998
- Fundamental
- Price
- ANTX $1.07
- NTIP $1.31
- Analyst Decision
- ANTX Buy
- NTIP
- Analyst Count
- ANTX 2
- NTIP 0
- Target Price
- ANTX $2.00
- NTIP N/A
- AVG Volume (30 Days)
- ANTX 289.9K
- NTIP 15.9K
- Earning Date
- ANTX 08-12-2025
- NTIP 08-11-2025
- Dividend Yield
- ANTX N/A
- NTIP 8.00%
- EPS Growth
- ANTX N/A
- NTIP N/A
- EPS
- ANTX N/A
- NTIP N/A
- Revenue
- ANTX N/A
- NTIP $250,000.00
- Revenue This Year
- ANTX N/A
- NTIP N/A
- Revenue Next Year
- ANTX N/A
- NTIP N/A
- P/E Ratio
- ANTX N/A
- NTIP N/A
- Revenue Growth
- ANTX N/A
- NTIP N/A
- 52 Week Low
- ANTX $0.87
- NTIP $1.16
- 52 Week High
- ANTX $3.07
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- ANTX 45.19
- NTIP 59.32
- Support Level
- ANTX $1.07
- NTIP $1.20
- Resistance Level
- ANTX $1.11
- NTIP $1.30
- Average True Range (ATR)
- ANTX 0.04
- NTIP 0.06
- MACD
- ANTX 0.00
- NTIP 0.01
- Stochastic Oscillator
- ANTX 28.57
- NTIP 84.44
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.